Cadence Pharmaceuticals Inc (CADX) financial statements (2020 and earlier)

Company profile

Business Address 12481 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5762
Cash and cash equivalents5558
Short-term investments24
Restricted cash and investments11
Receivables96
Inventory, net of allowances, customer advances and progress billings96
Inventory96
Prepaid expense2
Prepaid expense and other current assets1
Other current assets0
Total current assets:7877
Noncurrent Assets
Property, plant and equipment22
Intangible assets, net (including goodwill)1112
Intangible assets, net (excluding goodwill)1112
Restricted cash and investments0 
Other noncurrent assets0
Prepaid expense and other noncurrent assets7
Total noncurrent assets:1321
TOTAL ASSETS:9198
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2619
Accounts payable86
Accrued liabilities1813
Debt11 
Asset retirement obligation 1
Deferred revenue and credits 2
Other undisclosed current liabilities (1)
Total current liabilities:3721
Noncurrent Liabilities
Long-term debt and lease obligation1929
Long-term debt, excluding current maturities1929
Liabilities, other than long-term debt10
Other liabilities10
Total noncurrent liabilities:1929
Total liabilities:5650
Stockholders' equity
Stockholders' equity attributable to parent3548
Common stock00
Additional paid in capital507495
Accumulated deficit(472)(448)
Total stockholders' equity:3548
TOTAL LIABILITIES AND EQUITY:9198

Income statement (P&L) ($ in millions)

12/31/2013
12/31/2012
Revenues11350
Revenue, net11350
Cost of revenue
(Cost of Goods and Services Sold)
(38)(23)
Other undisclosed gross profit 0
Gross profit:7527
Operating expenses(103)(104)
Other operating income, net0 
Other undisclosed operating income00
Operating loss:(28)(77)
Nonoperating income (expense)3(4)
Other nonoperating income80
Interest and debt expense(4)(4)
Loss from continuing operations before equity method investments, income taxes:(29)(85)
Other undisclosed income from continuing operations before income taxes44
Net loss available to common stockholders, diluted:(24)(81)

Comprehensive Income ($ in millions)

12/31/2013
12/31/2012
Net loss:(24)(81)
Other comprehensive loss (0)
Comprehensive loss, net of tax, attributable to parent:(24)(81)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: